{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:02:59Z","timestamp":1782705779481,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002947","name":"Anhui Medical University","doi-asserted-by":"crossref","award":["2021xkj134"],"award-info":[{"award-number":["2021xkj134"]}],"id":[{"id":"10.13039\/501100002947","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"DOI":"10.1186\/s12880-026-02261-y","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:34:48Z","timestamp":1773282888000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intratumoral and peritumoral habitat imaging based on multiparametric MRI to predict HER2-negative breast cancer subtypes: a multicenter study"],"prefix":"10.1186","volume":"26","author":[{"given":"Hongli","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingwang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weishu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"issue":"1","key":"2261_CR1","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13058-021-01492-x","volume":"23","author":"SP Gampenrieder","year":"2021","unstructured":"Gampenrieder SP, Rinnerthaler G, Tinchon C, Petzer A, Balic M, Heibl S, Schmitt C, Zabernigg AF, Egle D, Sandholzer M, et al. Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry. Breast Cancer Res. 2021;23(1):112.","journal-title":"Breast Cancer Res"},{"issue":"8","key":"2261_CR2","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/S1470-2045(21)00349-1","volume":"22","author":"MV Dieci","year":"2021","unstructured":"Dieci MV, Miglietta F. HER2: a never ending story. Lancet Oncol. 2021;22(8):1051\u20132.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2261_CR3","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12916-022-02346-9","volume":"20","author":"G Zhang","year":"2022","unstructured":"Zhang G, Ren C, Li C, Wang Y, Chen B, Wen L, Jia M, Li K, Mok H, Cao L, et al. Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status. BMC Med. 2022;20(1):142.","journal-title":"BMC Med"},{"issue":"1","key":"2261_CR4","doi-asserted-by":"publisher","first-page":"5112","DOI":"10.1038\/s41467-023-40715-x","volume":"14","author":"L-J Dai","year":"2023","unstructured":"Dai L-J, Ma D, Xu Y-Z, Li M, Li Y-W, Xiao Y, Jin X, Wu S-Y, Zhao Y-X, Wang H, et al. Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer. Nat Commun. 2023;14(1):5112.","journal-title":"Nat Commun"},{"issue":"8","key":"2261_CR5","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S1470-2045(21)00301-6","volume":"22","author":"C Denkert","year":"2021","unstructured":"Denkert C, Seither F, Schneeweiss A, Link T, Blohmer J-U, Just M, Wimberger P, Forberger A, Tesch H, Jackisch C, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021;22(8):1151\u201361.","journal-title":"Lancet Oncol"},{"issue":"17","key":"2261_CR6","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1200\/JCO.19.02488","volume":"38","author":"P Tarantino","year":"2020","unstructured":"Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, Marra A, Viale G, Trapani D, Cardoso F, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020;38(17):1951\u201362.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2261_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10549-022-06781-3","volume":"197","author":"R Chen","year":"2022","unstructured":"Chen R, Qi Y, Huang Y, Liu W, Yang R, Zhao X, Wu Y, Li Q, Wang Z, Sun X, et al. Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population. Breast Cancer Res Treat. 2022;197(1):189\u2013200.","journal-title":"Breast Cancer Res Treat"},{"key":"2261_CR8","doi-asserted-by":"publisher","first-page":"1053125","DOI":"10.3389\/fonc.2023.1053125","volume":"13","author":"X Hu","year":"2023","unstructured":"Hu X, Chen W, Li F, Ren P, Wu H, Zhang C, Gu K. Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic breast cancer and its clinical significance. Front Oncol. 2023;13:1053125.","journal-title":"Front Oncol"},{"issue":"2","key":"2261_CR9","doi-asserted-by":"publisher","first-page":"e222646","DOI":"10.1148\/radiol.222646","volume":"308","author":"T Ramtohul","year":"2023","unstructured":"Ramtohul T, Djerroudi L, Lissavalid E, Nhy C, Redon L, Ikni L, Djelouah M, Journo G, Menet E, Cabel L, et al. Multiparametric MRI and radiomics for the prediction of HER2-zero, -low, and -positive breast cancers. Radiology. 2023;308(2):e222646.","journal-title":"Radiology"},{"issue":"5","key":"2261_CR10","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1002\/jmri.28628","volume":"58","author":"X Bian","year":"2023","unstructured":"Bian X, Du S, Yue Z, Gao S, Zhao R, Huang G, Guo L, Peng C, Zhang L. Potential antihuman epidermal growth factor receptor 2 target therapy beneficiaries: the role of MRI-based radiomics in distinguishing human epidermal growth factor receptor 2-low status of breast cancer. J Magn Reson Imaging. 2023;58(5):1603\u201314.","journal-title":"J Magn Reson Imaging"},{"issue":"9","key":"2261_CR11","doi-asserted-by":"publisher","first-page":"6132","DOI":"10.1007\/s00330-024-10641-7","volume":"34","author":"S Zheng","year":"2024","unstructured":"Zheng S, Yang Z, Du G, Zhang Y, Jiang C, Xu T, Li B, Wang D, Qiu Y, Lin D, et al. Discrimination between HER2-overexpressing, -low-expressing, and -zero-expressing statuses in breast cancer using multiparametric MRI-based radiomics. Eur Radiol. 2024;34(9):6132\u201344.","journal-title":"Eur Radiol"},{"issue":"1","key":"2261_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.acra.2024.07.048","volume":"32","author":"W Liu","year":"2025","unstructured":"Liu W, Yang Y, Wang X, Li C, Liu C, Li X, Wen J, Lin X, Qin J. A comprehensive model outperformed the single radiomics model in noninvasively predicting the HER2 status in patients with breast cancer. Acad Radiol. 2025;32(1):24\u201336.","journal-title":"Acad Radiol"},{"issue":"1","key":"2261_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41523-023-00518-1","volume":"9","author":"D Mandair","year":"2023","unstructured":"Mandair D, Reis-Filho JS, Ashworth A. Biological insights and novel biomarker discovery through deep learning approaches in breast cancer histopathology. NPJ Breast Cancer. 2023;9(1):21.","journal-title":"NPJ Breast Cancer"},{"issue":"24","key":"2261_CR14","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1002\/cncr.31630","volume":"124","author":"S Napel","year":"2018","unstructured":"Napel S, Mu W, Jardim-Perassi BV, Aerts HJWL, Gillies RJ. Quantitative imaging of cancer in the postgenomic era: Radio(geno)mics, deep learning, and habitats. Cancer. 2018;124(24):4633\u201349.","journal-title":"Cancer"},{"issue":"1","key":"2261_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1148\/radiol.2018172462","volume":"288","author":"J Wu","year":"2018","unstructured":"Wu J, Cao G, Sun X, Lee J, Rubin DL, Napel S, Kurian AW, Daniel BL, Li R. Intratumoral spatial heterogeneity at perfusion MR imaging predicts recurrence-free survival in locally advanced breast cancer treated with neoadjuvant chemotherapy. Radiology. 2018;288(1):26\u201335.","journal-title":"Radiology"},{"issue":"1","key":"2261_CR16","doi-asserted-by":"publisher","first-page":"e222830","DOI":"10.1148\/radiol.222830","volume":"308","author":"Z Shi","year":"2023","unstructured":"Shi Z, Huang X, Cheng Z, Xu Z, Lin H, Liu C, Chen X, Liu C, Liang C, Lu C, et al. MRI-based quantification of intratumoral heterogeneity for predicting treatment response to neoadjuvant chemotherapy in breast cancer. Radiology. 2023;308(1):e222830.","journal-title":"Radiology"},{"issue":"1","key":"2261_CR17","doi-asserted-by":"publisher","first-page":"e241805","DOI":"10.1148\/radiol.241805","volume":"315","author":"Y Huang","year":"2025","unstructured":"Huang Y, Wang X, Cao Y, Lan X, Hu X, Mou F, Chen H, Gong X, Li L, Tang S, et al. Nomogram for predicting neoadjuvant chemotherapy response in breast cancer using MRI-based intratumoral heterogeneity quantification. Radiology. 2025;315(1):e241805.","journal-title":"Radiology"},{"issue":"1","key":"2261_CR18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1148\/radiol.2018180271","volume":"288","author":"RJ Gillies","year":"2018","unstructured":"Gillies RJ, Balagurunathan Y. Perfusion MR imaging of breast cancer: insights using habitat imaging. Radiology. 2018;288(1):36\u20137.","journal-title":"Radiology"},{"issue":"3","key":"2261_CR19","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1177\/08465371241231573","volume":"75","author":"R Xu","year":"2024","unstructured":"Xu R, Yu D, Luo P, Li X, Jiang L, Chang S, Li G. Do habitat MRI and fractal analysis help distinguish triple-negative breast cancer from non-triple-negative breast carcinoma. Can Assoc Radiol J. 2024;75(3):584\u201392.","journal-title":"Can Assoc Radiol J"},{"key":"2261_CR20","doi-asserted-by":"publisher","first-page":"1595157","DOI":"10.3389\/fonc.2025.1595157","volume":"15","author":"A Wang","year":"2025","unstructured":"Wang A, He M, Zhang C, Zheng Y, Song Y, Wang C, Ma M, Yang G. Intravoxel incoherent motion-based habitat imaging for the prediction of immunohistochemistry in patients with breast cancer. Front Oncol. 2025;15:1595157.","journal-title":"Front Oncol"},{"issue":"4","key":"2261_CR21","doi-asserted-by":"publisher","first-page":"e192561","DOI":"10.1001\/jamanetworkopen.2019.2561","volume":"2","author":"N Braman","year":"2019","unstructured":"Braman N, Prasanna P, Whitney J, Singh S, Beig N, Etesami M, Bates DDB, Gallagher K, Bloch BN, Vulchi M, et al. Association of peritumoral radiomics with tumor biology and pathologic response to preoperative targeted therapy for HER2 (ERBB2)\u2013positive breast cancer. JAMA Netw Open. 2019;2(4):e192561.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"2261_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.diii.2017.01.001","volume":"98","author":"DA Spak","year":"2017","unstructured":"Spak DA, Plaxco JS, Santiago L, Dryden MJ, Dogan BE. BI-RADS \u00ae fifth edition: a summary of changes. Diagn Interv Imaging. 2017;98(3):179\u201390.","journal-title":"Diagn Interv Imaging"},{"issue":"2","key":"2261_CR23","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1148\/radiol.2020191145","volume":"295","author":"A Zwanenburg","year":"2020","unstructured":"Zwanenburg A, Valli\u00e8res M, Abdalah MA, Aerts HJWL, Andrearczyk V, Apte A, Ashrafinia S, Bakas S, Beukinga RJ, Boellaard R, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295(2):328\u201338.","journal-title":"Radiology"},{"issue":"12","key":"2261_CR24","doi-asserted-by":"publisher","first-page":"8211","DOI":"10.21037\/qims-24-558","volume":"14","author":"P-Q Wu","year":"2024","unstructured":"Wu P-Q, Guo F-L, Wang J, Gao Y, Feng S-T, Chen S-L, Ma J, Liu Y-B. Development and validation of a dynamic contrast-enhanced magnetic resonance imaging-based habitat and peritumoral radiomic model to predict axillary lymph node metastasis in patients with breast cancer: a retrospective study. Quant Imaging Med Surg. 2024;14(12):8211\u201326.","journal-title":"Quant Imaging Med Surg"},{"issue":"1","key":"2261_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12943-020-01292-5","volume":"20","author":"Y-P Chen","year":"2021","unstructured":"Chen Y-P, Lv J-W, Mao Y-P, Li X-M, Li J-Y, Wang Y-Q, Xu C, Li Y-Q, He Q-M, Yang X-J, et al. Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses. Mol Cancer. 2021;20(1):14.","journal-title":"Mol Cancer"},{"issue":"11","key":"2261_CR26","doi-asserted-by":"publisher","first-page":"4408","DOI":"10.1016\/j.acra.2024.06.003","volume":"31","author":"W Mai","year":"2024","unstructured":"Mai W, Tan J, Zhang L, Wang L, Zhang D, Shi C, Liu X. Predicting high-risk capsular features in pleomorphic adenoma of the parotid gland through a nomogram model based on ADC imaging. Acad Radiol. 2024;31(11):4408\u201318.","journal-title":"Acad Radiol"},{"issue":"2","key":"2261_CR27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1158\/1078-0432.CCR-14-0990","volume":"21","author":"JPB O\u2019Connor","year":"2015","unstructured":"O\u2019Connor JPB, Rose CJ, Waterton JC, Carano RAD, Parker GJM, Jackson A. Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome. Clin Cancer Res. 2015;21(2):249\u201357.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2261_CR28","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.3390\/cancers15102664","volume":"15","author":"Y Hou","year":"2023","unstructured":"Hou Y, Nitta H, Li Z. HER2 intratumoral heterogeneity in breast cancer, an evolving concept. Cancers. 2023;15(10):2664.","journal-title":"Cancers"},{"issue":"4","key":"2261_CR29","doi-asserted-by":"publisher","first-page":"zcae046","DOI":"10.1093\/narcan\/zcae046","volume":"6","author":"J Jim\u00e9nez-Santos Mar\u00eda","year":"2024","unstructured":"Jim\u00e9nez-Santos Mar\u00eda J, Garc\u00eda-Mart\u00edn S, Rubio-Fern\u00e1ndez M, G\u00f3mez-L\u00f3pez G, Al-Shahrour F. Spatial transcriptomics in breast cancer reveals tumour microenvironment-driven drug responses and clonal therapeutic heterogeneity. NAR Cancer. 2024;6(4):zcae046.","journal-title":"NAR Cancer"},{"key":"2261_CR30","doi-asserted-by":"publisher","first-page":"110434","DOI":"10.1016\/j.mri.2025.110434","volume":"122","author":"M Cao","year":"2025","unstructured":"Cao M, Liu X, Yang A, Xu Y, Zhang Q, Cao Y. Prediction of HER-2 expression status in breast cancer based on multi-parameter MRI intratumoral and peritumoral radiomics. Magn Reson Imaging. 2025;122:110434.","journal-title":"Magn Reson Imaging"},{"issue":"3","key":"2261_CR31","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","volume":"21","author":"D Hanahan","year":"2012","unstructured":"Hanahan D, Coussens Lisa M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309\u201322.","journal-title":"Cancer Cell"},{"issue":"1","key":"2261_CR32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41523-021-00265-1","volume":"7","author":"I Schlam","year":"2021","unstructured":"Schlam I, Swain SM. HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. NPJ Breast Cancer. 2021;7(1):56.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"2261_CR33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13058-024-01837-2","volume":"26","author":"PM Morla-Barcelo","year":"2024","unstructured":"Morla-Barcelo PM, Laguna-Macarrilla D, Cordoba O, Matheu G, Oliver J, Roca P, Nadal-Serrano M, Sastre-Serra J. Unraveling malignant phenotype of peritumoral tissue: transcriptomic insights into early-stage breast cancer. Breast Cancer Res. 2024;26(1):89.","journal-title":"Breast Cancer Res"},{"issue":"13","key":"2261_CR34","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.3390\/cancers15133450","volume":"15","author":"A Michot","year":"2023","unstructured":"Michot A, Lagarde P, Lesluyes T, Darbo E, Neuville A, Baud J, Perot G, Bonomo I, Maire M, Michot M, et al. Analysis of the peritumoral tissue unveils cellular changes associated with a high risk of recurrence. Cancers. 2023;15(13):3450.","journal-title":"Cancers"},{"issue":"10","key":"2261_CR35","doi-asserted-by":"publisher","first-page":"e70036","DOI":"10.1002\/ctm2.70036","volume":"14","author":"X Cheng","year":"2024","unstructured":"Cheng X, Cao Y, Liu X, Li Y, Li Q, Gao D, Yu Q. Single-cell and spatial omics unravel the spatiotemporal biology of tumour border invasion and haematogenous metastasis. Clin Transl Med. 2024;14(10):e70036.","journal-title":"Clin Transl Med"},{"key":"2261_CR36","doi-asserted-by":"publisher","first-page":"1570696","DOI":"10.3389\/fcell.2025.1570696","volume":"13","author":"Y Wu","year":"2025","unstructured":"Wu Y, Shi Y, Luo Z, Zhou X, Chen Y, Song X, Liu S. Spatial multi-omics analysis of tumor-stroma boundary cell features for predicting breast cancer progression and therapy response. Front Cell Dev Biol. 2025;13:1570696.","journal-title":"Front Cell Dev Biol"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-026-02261-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-026-02261-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-026-02261-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:40:36Z","timestamp":1776670836000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12880-026-02261-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2261"],"URL":"https:\/\/doi.org\/10.1186\/s12880-026-02261-y","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been performed in accordance with the Declaration of Helsinki. The Institutional Review Board of the First Affiliated Hospital of Anhui Medical University approved the study and waived the requirement for informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"198"}}